Schizophrenia Drugs Said to Raise Stroke Risk in Dementia Patients
Quick Links
The Reuters news agency reported today that Eli Lilly and Co. has notified doctors of a significant increase in the risk for stroke and death that it has observed in demented elderly patients who take its drug Zyprexa. This antipsychotic is approved for schizophrenia but is increasingly being used to treat behavioral problems, such as delusions and aggression, in people with dementia including Alzheimer’s disease. Doctors prescribe this drug for nursing home patients and others who still live at home. Such “off-label" use is legal, but Zyprexa is not officially approved for dementia. The company apparently sent a letter to doctors that it had found this increased risk in five clinical trials, the Wall Street Journal reported today. Johnson and Johnson warned last April that its schizophrenia drug Risperdal, too, increases the risk for stroke in elderly patients with dementia.—Adapted from Reuters .
Comments
Medical University of Lodz, LZ, Poland
No surprise at all. As dementia patients are already at higher risk for stroke due to metabolic disturbances that are already there, both in vascular and Alzheimer's disease, not mentioning age alone...The real question is whether this is the beginning of the end of the extensive use of atypicals in schizophrenia, and, particularly, in affective disorders. Atypicals lack extrapyramidal phenotype seen for classical neuroleptics, but what if they, instead, shorten patients' lives? Large observational studies are urgently needed to establish atypicals' "real life" safety profile in every indication. "Yellow card" is already here!